EUVIMEDEUVIMED entdecken
Crossref

Quinazoline‐oxindole hybrids as angiokinase inhibitors and anticancer agents: Design, synthesis, biological evaluation, and molecular docking studies

Yasmin M Syam, Somaia S Abd El-Karim, Heba T Abdel-Mohsen

Archiv der Pharmazie · 2024-10 · 357 (10)

DOI: 10.1002/ardp.202300682 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 12.07.2024. Verfasst von Yasmin M Syam und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Therapeutic Chemistry, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Cairo, Egypt. Hauptthemen laut MEDLINE: Antineoplastic Agents, Quinazolines, Molecular Docking Simulation, Drug Design. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Science, Technology & Innovation Funding Authority (STDF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Two new sets of quinazoline‐oxindole 8a–l and quinazoline‐dioxoisoindoline 10a–d hybrids were designed as type II angiokinase inhibitors and anticancer agents. The design strategy was adjusted to account for the quinazoline scaffold's placement in the target kinases' hinge region, where it would form hydrogen bonding and hydrophobic interactions with the important amino acids to stabilize it, and the amide group's occupation in the gate region, which would direct the oxindole scaffold toward the hydrophobic back pocket. The two sets of quinazolines 8a–l and 10a–d displayed pronounced inhibitory activity on VEGFR‐2 (IC 50 = 0.46–2.20 µM). The quinazoline‐oxindole hybrids 8d , 8f , and 8h displayed IC 50 = 0.46, 0.49, and 0.49 µM, respectively. Compound 8f demonstrated potent multikinase activity with IC 50 values of 0.95 and 0.67 µM against FGFR‐1 and BRAF, respectively. Additionally, compound 8f showed significant anticancer activity against National Cancer Institute's cancer cell lines, with GI 50 reaching 1.21 µM. Analysis of the impact of compound 8f on the MDA‐MB‐231 cell line's cell cycle and apoptosis revealed that 8f stalled the cell cycle at the G2/M phase and promoted its necrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsQuinazolinesMolecular Docking SimulationDrug DesignOxindolesProtein Kinase InhibitorsCell ProliferationVascular Endothelial Growth Factor Receptor-2Drug Screening Assays, AntitumorHumansStructure-Activity RelationshipCell Line, TumorMolecular StructureApoptosisDose-Response Relationship, DrugReceptor, Fibroblast Growth Factor, Type 1Proto-Oncogene Proteins B-rafInhibitory Concentration 50

Stichwörter der Autor:innen

angiokinase inhibitorsanticancer agentsoxindolequinazoline

Substanzen

Antineoplastic AgentsQuinazolinesOxindolesProtein Kinase InhibitorsVascular Endothelial Growth Factor Receptor-2KDR protein, humanReceptor, Fibroblast Growth Factor, Type 1Proto-Oncogene Proteins B-rafFGFR1 protein, humanBRAF protein, human

Autor:innen und Institutionen

  • Department of Therapeutic Chemistry, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Cairo, Egypt.
  • Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Cairo, Egypt.

Förderung

  • Science, Technology & Innovation Funding Authority (STDF)

Zitieren

APA

Syam, Y. M., Abd El-Karim, S. S., & Abdel-Mohsen, H. T. (2024). Quinazoline‐oxindole hybrids as angiokinase inhibitors and anticancer agents: Design, synthesis, biological evaluation, and molecular docking studies. Archiv der Pharmazie, 357(10). https://doi.org/10.1002/ardp.202300682

Vancouver

Syam YM, Abd El-Karim SS, Abdel-Mohsen HT. Quinazoline‐oxindole hybrids as angiokinase inhibitors and anticancer agents: Design, synthesis, biological evaluation, and molecular docking studies. Archiv der Pharmazie. 2024;357(10). doi:10.1002/ardp.202300682

BibTeX
@article{Syam2024,
  author = {Syam, Yasmin M and Abd El-Karim, Somaia S and Abdel-Mohsen, Heba T},
  title = {Quinazoline‐oxindole hybrids as angiokinase inhibitors and anticancer agents: Design, synthesis, biological evaluation, and molecular docking studies},
  journal = {Archiv der Pharmazie},
  year = {2024},
  volume = {357},
  number = {10},
  doi = {10.1002/ardp.202300682}
}
Kostenlos starten →